These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26345283)

  • 1. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.
    Han K; Peyret T; Quartino A; Gosselin NH; Gururangan S; Casanova M; Merks JH; Massimino M; Grill J; Daw NC; Navid F; Jin J; Allison DE
    Br J Clin Pharmacol; 2016 Jan; 81(1):148-60. PubMed ID: 26345283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of bevacizumab in cancer patients with external validation.
    Han K; Peyret T; Marchand M; Quartino A; Gosselin NH; Girish S; Allison DE; Jin J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):341-51. PubMed ID: 27329360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies.
    Gojo J; Sauermann R; Knaack U; Slavc I; Peyrl A
    Drugs R D; 2017 Sep; 17(3):469-474. PubMed ID: 28577293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
    Albers S; Meibohm B; Mir TS; Läer S
    Br J Clin Pharmacol; 2008 Apr; 65(4):511-22. PubMed ID: 17995971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.
    Turner DC; Navid F; Daw NC; Mao S; Wu J; Santana VM; Neel M; Rao B; Willert JR; Loeb DM; Harstead KE; Throm SL; Freeman BB; Stewart CF
    Clin Cancer Res; 2014 May; 20(10):2783-92. PubMed ID: 24637635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
    Lu JF; Bruno R; Eppler S; Novotny W; Lum B; Gaudreault J
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):779-86. PubMed ID: 18205003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
    Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
    Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.
    Vogt W
    Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics.
    Landersdorfer CB; Findling RL; Frazier JA; Kafantaris V; Kirkpatrick CM
    Clin Pharmacokinet; 2017 Jan; 56(1):77-90. PubMed ID: 27393139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors.
    Minichmayr IK; Knaack U; Gojo J; Senfter D; Haberler C; Azizi AA; Mayr L; Zeitlinger M; Peyrl A
    Paediatr Drugs; 2024 Jul; 26(4):429-440. PubMed ID: 38587585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.